CliffBio
small molecule

IOPAMIDOL-300

IOPAMIDOL

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameIOPAMIDOL-300
Active ingredientIOPAMIDOL
Strength61%
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalApril 1997
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

IOPAMIDOL-300 patent cliff — loss of exclusivity — | CliffBio